1. Scope by product: • Starter: ancestry, traits, and wellness. • Advanced: adds genetic vulnerability to health conditions, carrier status, and pharmacogenetics. • ULTRA: WGS with an approximate target average coverage of 30×, with analysis of common and rare variants. Minors can take the test, but only their father, mother, or legal guardian can register it and contract the service, and they are the ones who receive the results. The report includes the same information as that for an adult with the same product: before contracting, it is advisable to consider that it may reveal predispositions to adult conditions and information about relatives. 2. Nature of results: Reports are predictive and informative. They do not constitute a diagnosis, do not confirm or rule out diseases, and should not be used alone to initiate, suspend, or adjust treatments. Before any health decision, the result must be evaluated by a qualified professional and, when the decision depends on a specific variant, that variant must be confirmed by an independent validated clinical method in an accredited laboratory. 3. Ancestry and traits: Ancestry estimates are probabilistic and depend on reference databases; regions with lower representation may show lower resolution. Genetic ancestry is not equivalent to citizenship, legal identity, or documented genealogy. Traits are based on published associations and do not reflect the full complexity of the phenotype. 4. Inherited conditions and residual risk: A "no reportable variants" result reduces but does not eliminate risk. The detection rate varies by gene, variant type, and ancestry. Variants outside the methodological scope or not yet described may exist. No technique is infallible: there may be results that are not confirmed later and present variants that are not detected. 5. Pharmacogenetics: Describes how certain variants can influence the metabolism or response to drugs. It does not determine efficacy or safety on its own. Factors such as age, kidney/liver function, comorbidities, interactions, and dosage are determining factors. In some genes, the identification of complex haplotypes, duplications/deletions, or hybrid alleles may require additional techniques not included. Do not change your medication without consulting your doctor. 6. Specific warnings (e.g., BRCA1 and BRCA2): • In Advanced, a specific set of variants is evaluated, which does not cover all possible variants or all structural alterations. • ULTRA allows for the analysis of much broader regions of these genes, but does not guarantee complete reading of each region or detection of all variant types. • The absence of findings does not exclude other variants that influence risk. • Any result must be confirmed according to point 2 before making medical decisions. 7. Technical limitations: Target average coverage is not achieved uniformly at all positions, and there are zones and variant types that are difficult to detect, such as: • CNVs and complex or balanced rearrangements; • repeat expansions (e.g., FMR1); • complex haplotypes (e.g., HLA), pseudogenes, low-complexity regions, or high homology. The analysis is performed on saliva and is primarily designed for germline variants: it is not validated for the systematic detection of somatic variants or low-fraction mosaicisms. In microarrays, the analysis is limited to predefined markers; any extension by imputation depends on reference methods and populations and does not directly measure these variants. Scientific evidence evolves, and variant classification may change over time. 8. Variants of uncertain significance (VUS): Standard reports include only variants with sufficient evidence to be classified as pathogenic or likely pathogenic. Variants of uncertain significance are not included in the standard report, even if the analysis can detect them. If you expressly request it, you can separately contract a specific report for variants of uncertain significance, at the price indicated on the platform; this report is exploratory and no medical decisions should be made based on it until sufficient evidence or clinical confirmation exists. 9. Emotional impact and support: Genetic information can have an emotional impact and may reveal unexpected findings, including family relationships different from those expected, with implications for biological relatives. Free educational materials are available on the platform before and after the analysis, and you can contract a consultation with qualified genetic professionals, at the price indicated on the platform, except in Spain for Advanced and ULTRA, which require a prior medical prescription and include a post-results consultation free of charge. We recommend discussing the results with your doctor and a genetic counseling professional. 10. Responsible use of data and external tools: If you download your raw data and use it in third-party services, interpretations may differ from those of tellmeGen. We cannot guarantee the accuracy of external results or offer support for them. 11. Sample quality and repetitions: DNA quality and quantity, collection, and transport influence the validity of the analysis. If a sample is inadequate due to causes not attributable to the user, the current Information Update and Sample Repetition Policy, visible on the platform before contracting, will apply. 12. Report versioning: The content and scope of reports may vary due to product versions, methodological updates, or new evidence, and an update may modify, qualify, or withdraw a previous result. The report date indicates the applicable version.

What do your genes say about you? Start your journey today.

Haven't you taken our DNA test yet?

Get your genetic test and find out all about yourself.